ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
In the gynecologic expansion cohort of the first-in-human, phase 1 MYTHIC trial, the combination of lunresertib (a PKMYT1 inhibitor) and camonsertib (an ATR inhibitor) produced durable objective responses in heavily…
In the gynecologic expansion cohort of the first-in-human, phase 1 MYTHIC trial, the combination of lunresertib (a PKMYT1 inhibitor) and camonsertib (an ATR inhibitor) produced durable objective responses in heavily…
✓ Primary source cited
Last reviewed
Clinical Trials
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
Participants age 18 Years and older with Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-09-22
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-09-22
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Participants age 18 Years and older with Endometrial Cancer, Recurrent or Progressive Endometrial Cancer who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-09-09
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-09-09
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Participants age 18 Years and older with Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed
2026-08-21
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-21
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Adults with advanced, heavily pretreated endometrial cancer (n=27 in this cohort), enrolled in the gynecologic expansion cohort of a first-in-human, phase 1 trial. A separate cohort of the SAME trial (n=24) enrolled patients with platinum-resistant ovarian cancer; both cohorts' results are reported together here since they come from the same combination and the same trial, though this record's cancer_type taxonomy tag reflects the endometrial cohort specifically.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.